Sections

Sort by
Previous Page Page 1 of 56 Next Page
  1. Case report

    Immunotherapy-associated autoimmune hemolytic anemia

    Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-...

    Uqba Khan, Farman Ali, Muhammad Siddique Khurram, Awais Zaka and Tarik Hadid

    Journal for ImmunoTherapy of Cancer 2017 5:15

    Published on: 21 February 2017

  2. Case report

    Nivolumab induced myxedema crisis

    Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed...

    Uqba Khan, Humaira Rizvi, Dahlia Sano, Jane Chiu and Tarik Hadid

    Journal for ImmunoTherapy of Cancer 2017 5:13

    Published on: 21 February 2017

  3. Commentary

    FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer

    Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Ji...

    Stefan N. Symeonides, Stephen M. Anderton and Alan Serrels

    Journal for ImmunoTherapy of Cancer 2017 5:17

    Published on: 21 February 2017

  4. Case report

    PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation

    Allogeneic hematopoietic stem cell transplantation and checkpoint blockade therapy are immune-based therapies that have activity in selected refractory hematologic malignancies. Interest has developed in combi...

    James Godfrey, Michael R. Bishop, Sahr Syed, Elizabeth Hyjek and Justin Kline

    Journal for ImmunoTherapy of Cancer 2017 5:11

    Published on: 21 February 2017

  5. Commentary

    Immunotherapy resistance: the answers lie ahead – not in front – of us

    Mechanisms of innate and adaptive resistance to checkpoint blockade immunotherapy are under intense investigation with a view to broadening the therapeutic potential of this form of treatment. In a recent manu...

    Miles C. Andrews and Jennifer A. Wargo

    Journal for ImmunoTherapy of Cancer 2017 5:10

    Published on: 21 February 2017

  6. Case report

    Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

    Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-...

    Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Ozgun, Ciara Kelly, Meredith McKean, Jennifer McQuade, Mary Ann Thompson, Igor Puzanov, John P. Greer, Suthee Rapisuwon, Michael Postow, Michael A. Davies, Zeynep Eroglu and Douglas Johnson

    Journal for ImmunoTherapy of Cancer 2017 5:8

    Published on: 21 February 2017

  7. Research article

    Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

    Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-depend...

    Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley and Jeffrey Schlom

    Journal for ImmunoTherapy of Cancer 2017 5:20

    Published on: 21 February 2017

  8. Research article

    Gene expression markers of Tumor Infiltrating Leukocytes

    Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the in...

    Patrick Danaher, Sarah Warren, Lucas Dennis, Leonard D’Amico, Andrew White, Mary L. Disis, Melissa A. Geller, Kunle Odunsi, Joseph Beechem and Steven P. Fling

    Journal for ImmunoTherapy of Cancer 2017 5:18

    Published on: 21 February 2017

  9. Review

    Combination immunotherapy: a road map

    Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent yea...

    Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton and Jedd D. Wolchok

    Journal for ImmunoTherapy of Cancer 2017 5:16

    Published on: 21 February 2017

  10. Research article

    Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation

    Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with...

    Mohanad H. Nada, Hong Wang, Grefachew Workalemahu, Yoshimasa Tanaka and Craig T. Morita

    Journal for ImmunoTherapy of Cancer 2017 5:9

    Published on: 21 February 2017

  11. Research article

    CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo

    Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate wit...

    Gray Kueberuwa, Hannah Gornall, Erik Marcelo Alcantar-Orozco, Deborah Bouvier, Zainul Abedin Kapacee, Robert Edward Hawkins and David Edward Gilham

    Journal for ImmunoTherapy of Cancer 2017 5:14

    Published on: 21 February 2017

  12. Erratum

    Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

    Marc Uemura, Faisal Fa’ak, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff and Adi Diab

    Journal for ImmunoTherapy of Cancer 2017 5:7

    Published on: 18 January 2017

    The original article was published in Journal for ImmunoTherapy of Cancer 2016 4:55

  13. Case report

    Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma

    Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases a...

    Kathryn E. Beckermann, Pradeep C. Jolly, Ju Y. Kim, Jennifer Bordeaux, Igor Puzanov, W. Kimryn Rathmell and Douglas B. Johnson

    Journal for ImmunoTherapy of Cancer 2017 5:1

    Published on: 17 January 2017

  14. Commentary

    It’s a long way to the top (if you want to personalize immunotherapy)

    Harnessing the immune system to attack tumor cells by targeting tumor-associated or –preferably– tumor-specific antigens has emerged as a promising but challenging treatment option for malignant lymphomas. Fol...

    Sarah Haebe and Oliver Weigert

    Journal for ImmunoTherapy of Cancer 2017 5:6

    Published on: 17 January 2017

  15. Case report

    Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

    Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by thes...

    Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka and Jose Lutzky

    Journal for ImmunoTherapy of Cancer 2017 5:3

    Published on: 17 January 2017

  16. Research article

    Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen

    We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune resp...

    Gilda G. Hillman, Lyndsey A. Reich, Shoshana E. Rothstein, Lisa M. Abernathy, Matthew D. Fountain, Kali Hankerd, Christopher K. Yunker, Joseph T. Rakowski, Eric Quemeneur and Philippe Slos

    Journal for ImmunoTherapy of Cancer 2017 5:4

    Published on: 17 January 2017

  17. Review

    A New VISTA on combination therapy for negative checkpoint regulator blockade

    Negative checkpoint regulators function to restrain T cell responses to maintain tolerance and limit immunopathology. However, in the setting of malignancy, these pathways work in concert to promote immune-med...

    Jie Deng, Isabelle Le Mercier, Anna Kuta and Randolph J. Noelle

    Journal for ImmunoTherapy of Cancer 2016 4:86

    Published on: 20 December 2016

  18. Case report

    Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature

    We report a case of sarcoidosis in a patient with metastatic melanoma managed with combination ipilimumab/nivolumab. Sarcoid development has been linked with single agent immunotherapy but, to our knowledge, i...

    Joshua E. Reuss, Paul R. Kunk, Anne M. Stowman, Alejandro A. Gru, Craig L. Slingluff and Elizabeth M. Gaughan

    Journal for ImmunoTherapy of Cancer 2016 4:94

    Published on: 20 December 2016

  19. Case report

    Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

    Checkpoint inhibitor immunotherapy is becoming an effective treatment modality for an increasing number of malignancies. As a result, autoinflammatory side-effects are also being observed more commonly in the ...

    Jared R. Lowe, Daniel J. Perry, April K. S. Salama, Clayton E. Mathews, Larry G. Moss and Brent A. Hanks

    Journal for ImmunoTherapy of Cancer 2016 4:89

    Published on: 20 December 2016

  20. Research article

    A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

    Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted a...

    Andrew S. Brohl, Nikhil I. Khushalani, Zeynep Eroglu, Joseph Markowitz, Ram Thapa, Y. Ann Chen, Ragini Kudchadkar and Jeffrey S. Weber

    Journal for ImmunoTherapy of Cancer 2016 4:85

    Published on: 20 December 2016

  21. Commentary

    Advances in immunotherapeutic strategies for colorectal cancer commentary on: tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients by Halama et al

    Colorectal cancer is a leading cause of cancer-related death in the United States, despite recent advances in treatment strategies. The immune system has been implicated in the pathogenesis of colorectal cance...

    Dustin A. Deming

    Journal for ImmunoTherapy of Cancer 2016 4:93

    Published on: 20 December 2016

Previous Page Page 1 of 56 Next Page
JITC logo

Advertisement